PROSTAT KANSERİ MOLEKÜLER MEKANİZMASINDA KODLANMAYAN RNA’LARIN ROLÜ

Kodlanmayan RNA’lar (ncRNA), bir açık okuma çerçevesi bulunmayan ve proteine çevrilemeyen işlevsel RNA transkriptleridir. NcRNA’lar transkripsiyon ve transkripsiyon sonrası işlemlerde düzenleyici rollere ve halen açıklanmaya devam eden çok sayıda hücresel fonksiyona sahiptir. NcRNA’lardan en iyi bilinenleri mikro RNA’lar (miRNA), hedefledikleri genlerin ya translasyonel baskılanmasına ya da mRNA yıkımına yol açarak gen ifadesini düzenleyen küçük (~22 nt) RNA molekülleridir. Uzun kodlanmayan RNA’lar (lncRNA), uzunluğu 200 nükleotidden daha büyük olan ve birçok alt sınıfı bulunan heterojen RNA’lardır. Bu RNA molekülleri DNA veya proteinler ile etkileşime girerek kromatin yeniden şekillenmesi, histon modifikasyonu, gen ifadesinin transkripsiyonel ve translasyonel düzenlenmesi gibi önemli işlevler üstlenirler. Hem miRNA’lar hem de lncRNA’lar prostat kanseri dahil birçok kanser çeşidinde düzensiz ifade edilmektedirler. Bu derleme, miRNA, lncRNA ve diğer ncRNA’ların prostat kanserinin moleküler biyolojisinde önemini açıklayarak prostat kanserinin ayırıcı tanısında ve hedeflenebilir tedavisinde kullanılabilirliğini vurgulamaktadır.

The Role of Non-Coding RNAs in Molecular Mechanism of Prostate Cancer

Non-coding RNAs (ncRNAs) are functional RNA transcripts, which do not have an open-reading frame and cannot be translated into protein. ncRNAs have mediator roles in the transcription and the post-transcription processes and have numerous cellular functions which still continue to be explored. The best known members of ncRNAs, the microRNAs (miRNAs), are small RNA molecules (~22 nt) which regulate the expressions of the targeted genes by either leading transcriptional repression or mRNA degradation. long non-coding RNAs (lncRNAs) which are longer than 200 nucleotides, are heterogenic RNAs which have many subclasses. These RNA molecules, by interacting with DNA or proteins, play key roles in chromatin remodeling, histone modification, and transcriptional and translational regulation of gene expression. miRNAs and lncRNAs are irregularly expressed in many types of cancer including prostate cancer. The present review discusses the importance of miRNA, lncRNA, and other ncRNAs in the molecular biology of prostate cancer and emphasizes their employability in the diagnosis and the targeted therapy to prostate cancer.

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. Jama. 1995;273(7):548-2.
3. Fedewa Stacey A, Ward Elizabeth M, Brawley Otis Jemal Ahmedin. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med. 2017;177(7):1040-2.
4. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SRet al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596.
5. Bussemakers MJ, Van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3:: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res.1999;59(23):5975-9.
6. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27(12):1788.
7. Ren S, Liu Y,XuW, Sun Y, Lu J, Wang F, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190(6):2278-7.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257-1.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan E, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513-8.
10. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608-6.
11. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PloS one. 2009;4(7):e6229.
12. Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010;8(4):529-8.
13. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166-6.
14. Liu DF, Wu JT, Wang JM, Liu QZ, Gao ZL, Liu YX. MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer. Asian Pac J Cancer Prev. 2012;13(7):3313-7.
15. Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T. et al. Combinations of serum prostate- specificantigenandplasmaexpressionlevelsoflet- 7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 2015;34(3):189-0.
16. Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 2010;5(4):e10147.
17. Tang G., Du R., Tang Z. Kuang Y. MiRNALet-7a mediates prostate cancer PC-3 cell invasion, migration by inducing epithelial-mesenchymal transition through CCR7/MAPK pathway. J Cell Biochem. 2018;119(4):3725-1.
18. Zhao B, Lu YL, Yang Y, Hu LB, Bai Y, Li RQ, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-beta1/ Smad signaling pathway. Cancer Biomark. 2018;21(3):613-0.
19. Chakravarthi B, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, et al. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Mol Cancer Res. 2018;16(7):1125-7.
20. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, et al. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res. 2015;13(4):681-8.
21. LiuX,LuoX,Wu Y, Xia D, Chen W, Fang Z, et al. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Cell Physiol Biochem. 2018;50(1):261-6.
22. Zhang G, TianX,Li Y, Wang Z, LiX,Zhu C. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to- mesenchymal transition by targeting ZEB1. Biomed Pharmacother. 2018;97:736-4.
23. Huang S, Wa Q, Pan J, PengX,Ren D, Huang Y, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-kappaB signaling in prostate cancer. J Exp Clin Cancer Res. 2017;36(1):173.
24. Khorasani M, Teimoori-Toolabi L, Farivar TN, Asgari M, Abolhasani M, Shahrokh H, et al. Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer. Cancer Biomark. 2018;22(1):19-8.
25. Li JZ, Li J, Wang HQ, LiX,Wen B, Wang YJ. MiR- 141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017;482(4):1381-6.
26. Li Z, Ma YY, Wang J, Zeng XF, Li R, Kang W, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther. 2016;9:139-8.
27. Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017;8:14270.
28. PengP,ChenT,WangQ,ZhangY,ZhengF,Huang S. et al. Decreased miR-218-5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. Oncol Res Treat. 2019;42(4):165-5.
29. Yin W, Chen J, Wang G, Zhang D. MicroRNA106b functions as an oncogene and regulates tumorviability and metastasis by targeting LARP4B in prostate cancer. Mol Med Rep. 2019;20(2):951-8.
30. Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene. 2018;658:152-8.
31. Hao P, Kang B, Yao G, Hao W, Ma F. MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC. Oncol Lett. 2018;15(4):4323-9.
32. Wang Y,XuH, Si L, Li Q, ZhuX,Yu T. et al. MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 2018;78(7):479- 0.
33. Fang Y, Qiu J, Jiang ZB,XuSR, Zhou ZH, He RL. Increased serum levels of miR-214 in patients with PCa with bone metastasis may serve as a potential biomarker by targeting PTEN. Oncol Lett. 2019;17(1):398-5.
34. Zhang M, Li H, Zhang Y, Li H. Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1. Oncol Lett. 2019;17(2):2257-5.
35. Fan H, Zhang YS. miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2. Eur Rev Med Pharmacol Sci. 2019;23(2):539-6.
36. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014;42(1):609-1.
37. Hydbring P, Badalian-Very G. Clinical applications of microRNAs. F1000Research. 2013;2:136-2.
38. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA. 2000;97(22):12216-1.
39. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non‐coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011;102(1):245-2.
40. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29(8):742.
41. Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JCY, Hosono Y, et al. Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018;50(6):814.
42. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta. 2013;1832(10):1613-3.
43. Zhu M, Chen Q, LiuX,Sun Q, ZhaoX,Deng R, et al. lnc RNA H19/miR‐675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J. 2014;281(16):3766-3775.
44. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6(5):255-1.
45. Salameh A, Lee AK, Cardo-Vila M, Nunes DN, Efstathiou E, Staquicini FI, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci USA. 2015;112(27):8403-8.
46. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth- promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004;23(2):605.